## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6881691/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. Journal of Hepatology, 2022, 76, 107-114.	1.8	21
2	The pituitary tumourâ€ŧransforming gene 1/deltaâ€ŀike homologue 1 pathway plays a key role in liver fibrogenesis. Liver International, 2022, 42, 651-662.	1.9	5
3	Pituitary Tumor-Transforming Gene 1/Delta like Non-Canonical Notch Ligand 1 Signaling in Chronic Liver Diseases. International Journal of Molecular Sciences, 2022, 23, 6897.	1.8	5
4	Mesoporous silica coated CeO2 nanozymes with combined lipid-lowering and antioxidant activity induce long-term improvement of the metabolic profile in obese Zucker rats. Nanoscale, 2021, 13, 8452-8466.	2.8	12
5	Treatment of Hepatic Fibrosis in Mice Based on Targeted Plasmonic Hyperthermia. ACS Nano, 2021, 15, 7547-7562.	7.3	25
6	Validation of a Gas Chromatography-Mass Spectrometry Method for the Measurement of the Redox State Metabolic Ratios Lactate/Pyruvate and β-Hydroxybutyrate/Acetoacetate in Biological Samples. International Journal of Molecular Sciences, 2021, 22, 4752.	1.8	7
7	Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. Antioxidants, 2021, 10, 660.	2.2	41
8	Scalable synthesis of multicomponent multifunctional inorganic core@mesoporous silica shell nanocomposites. Materials Science and Engineering C, 2021, 128, 112272.	3.8	9
9	The loss of DHX15 impairs endothelial energy metabolism, lymphatic drainage and tumor metastasis in mice. Communications Biology, 2021, 4, 1192.	2.0	5
10	Monocyte Subsets Are Differently Associated with Infarct Size, Left Ventricular Function, and the Formation of a Potentially Arrhythmogenic Scar in Patients with Acute Myocardial Infarction. Journal of Cardiovascular Translational Research, 2020, 13, 722-730.	1.1	5
11	Follow-Up After Myocardial Infarction toÂExplore the Stability of Arrhythmogenic Substrate. JACC: Clinical Electrophysiology, 2020, 6, 207-218.	1.3	16
12	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. Hepatology, 2020, 72, 1267-1282.	3.6	37
13	Cerium Oxide Nanoparticles: Advances in Biodistribution, Toxicity, and Preclinical Exploration. Small, 2020, 16, e1907322.	5.2	85
14	Biopsia lÃquida: un reto para el laboratorio de diagnóstico clÃnico. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
15	Liquid biopsy. A challenge for clinical laboratories. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
16	Cerium oxide nanoparticles improve liver regeneration after acetaminophen-induced liver injury and partial hepatectomy in rats. Journal of Nanobiotechnology, 2019, 17, 112.	4.2	38
17	Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. Cells, 2019, 8, 1311.	1.8	27
18	Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules, 2019, 9, 425.	1.8	34

#	Article	IF	CITATIONS
19	Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. Scientific Reports, 2019, 9, 12848.	1.6	35
20	Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats. PLoS ONE, 2019, 14, e0218716.	1.1	13
21	FRI-334-Cerium oxide nanoparticles present antilipogenic and antiinflammatory effects in rats with diet-induced non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 70, e543.	1.8	1
22	Neutrophil Gelatinaseâ€Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019, 70, 319-333.	3.6	114
23	Catalytic Cerium Oxide Nanoparticles in Nanomedicine and Their Use in Liver Diseases. , 2019, , .		1
24	Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes. International Journal of Molecular Sciences, 2019, 20, 5959.	1.8	28
25	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver International, 2019, 39, 1246-1255.	1.9	64
26	Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 28-34.	1.2	11
27	An evaluation of the SENTiFIT 270 analyser for quantitation of faecal haemoglobin in the investigation of patients with suspected colorectal cancer. Clinical Chemistry and Laboratory Medicine, 2018, 56, 625-633.	1.4	11
28	Graphene–Dendrimer Nanostars for Targeted Macrophage Overexpression of Metalloproteinase 9 and Hepatic Fibrosis Precision Therapy. Nano Letters, 2018, 18, 5839-5845.	4.5	40
29	Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases. Future Oncology, 2017, 13, 875-882.	1.1	2
30	Identification of the potentially arrhythmogenic substrate in the acute phase of ST-segment elevation myocardial infarction. Heart Rhythm, 2017, 14, 592-598.	0.3	11
31	The Role of Akt in Chronic Liver Disease and Liver Regeneration. Seminars in Liver Disease, 2017, 37, 011-016.	1.8	29
32	Letter in reply: Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases. Future Oncology, 2017, 13, 1135-1136.	1.1	0
33	Prognostic value of plasma apelin concentrations at admission in patients with ST-segment elevation acute myocardial infarction. Clinical Biochemistry, 2017, 50, 279-284.	0.8	13
34	Intrinsic and Extrinsic Properties Affecting Innate Immune Responses to Nanoparticles: The Case of Cerium Oxide. Frontiers in Immunology, 2017, 8, 970.	2.2	45
35	Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. World Journal of Castroenterology, 2017, 23, 3163.	1.4	23
36	Fibrinogen α-Chain as a Serum Marker of Liver Disease. Biomarkers in Disease, 2017, , 493-511.	0.0	2

#	Article	IF	CITATIONS
37	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. PLoS ONE, 2016, 11, e0157371.	1.1	20
38	Aktâ€mediated foxo1 inhibition is required for liver regeneration. Hepatology, 2016, 63, 1660-1674.	3.6	55
39	Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases. Translational Oncology, 2016, 9, 445-452.	1.7	2
40	Sipa1l1 is an early biomarker of liver fibrosis in CCl4-treated rats. Biology Open, 2016, 5, 858-865.	0.6	4
41	Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. International Journal of Cardiology, 2016, 223, 458-464.	0.8	19
42	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 914-920.	1.8	35
43	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. Scientific Reports, 2016, 6, 32341.	1.6	101
44	Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. Journal of Hepatology, 2016, 64, 691-698.	1.8	178
45	Clinical utility of one versus two faecal immunochemical test samples in the detection of advanced colorectal neoplasia in symptomatic patients. Clinical Chemistry and Laboratory Medicine, 2016, 54, 125-32.	1.4	29
46	Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. Hepatology, 2016, 63, 207-216.	3.6	18
47	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. PLoS ONE, 2015, 10, e0128145.	1.1	97
48	Overexpression of angiopoletinâ $\in 2$ in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver International, 2015, 35, 1383-1392.	1.9	31
49	Pathophysiology of Portal Hypertension. , 2015, , 3631-3665.		8
50	Fibrinogen α-Chain as a Serum Marker of Liver Disease. Exposure and Health, 2015, , 1-20.	2.8	0
51	Lack of a 5.9 kDa Peptide C-Terminal Fragment of Fibrinogen α Chain Precedes Fibrosis Progression in Patients with Liver Disease. PLoS ONE, 2014, 9, e109254.	1.1	12
52	Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta, 2014, 435, 53-58.	0.5	13
53	Hepatorenal Syndrome and Other Liver-Related Kidney Diseases. , 2014, , 268-276.		0
54	Microwave-assisted derivatization: Application to steroid profiling by gas chromatography/mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 8-13.	1.2	24

#	Article	IF	CITATIONS
55	Risk Stratification for Advanced Colorectal Neoplasia According to Fecal Hemoglobin Concentration in a Colorectal Cancer Screening Program. Gastroenterology, 2014, 147, 628-636.e1.	0.6	94
56	Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. Journal of Hepatology, 2014, 61, 35-42.	1.8	98
57	Pathophysiology of Portal Hypertension. , 2014, , 1-41.		1
58	PCA3 in the detection and management of early prostate cancer. Tumor Biology, 2013, 34, 1337-1347.	0.8	48
59	Impaired liver regeneration in Ldlrâ^'/â^' mice is associated with an altered hepatic profile of cytokines, growth factors, and lipids. Journal of Hepatology, 2013, 59, 731-737.	1.8	18
60	Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut, 2013, 62, 138-145.	6.1	47
61	Bacterial lipopolyshaccaride inhibits CB2 receptor expression in human monocytic cells. Gut, 2013, 62, 1089-1091.	6.1	9
62	Factors Involved in Extracellular Matrix Turnover in Human Derived Cardiomyocytes. Cellular Physiology and Biochemistry, 2013, 32, 1125-1136.	1.1	13
63	Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis—a serological evaluation. Liver International, 2013, 33, 439-447.	1.9	50
64	Prevention of Fibrosis Progression in CCl <sub>4</sub> -Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 629-637.	1.3	56
65	Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. Journal of Hepatology, 2012, 57, 267-273.	1.8	191
66	ARFI, FibroScan®, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. Journal of Hepatology, 2012, 57, 281-287.	1.8	150
67	Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut, 2011, 60, 1404-1411.	6.1	60
68	Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis and Tissue Repair, 2011, 4, 19.	3.4	28
69	Angiogenesis and Vascular Growth in Liver Diseases. , 2011, , 343-359.		0
70	Apelin Mediates the Induction of Profibrogenic Genes in Human Hepatic Stellate Cells. Endocrinology, 2010, 151, 5306-5314.	1.4	58
71	Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation. Gastroenterology, 2010, 138, 147-158.e1.	0.6	68
72	Further Pharmacological and Genetic Evidence for the Efficacy of PIGF Inhibition in Cancer and Eye Disease. Cell, 2010, 141, 178-190.	13.5	243

#	Article	IF	CITATIONS
73	Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H550-H555.	1.5	69
74	LH/HCG stimulation of VEGF and adrenomedullin production by follicular fluid macrophages and luteinized granulosa cells. Reproductive BioMedicine Online, 2009, 18, 743-749.	1.1	17
75	Renal Function in Liver Disease. , 2009, , 261-267.		0
76	The hepatic apelin system: A new therapeutic target for liver disease. Hepatology, 2008, 48, 1193-1201.	3.6	113
77	Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 475-483.	1.3	150
78	Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Human Reproduction, 2007, 22, 669-675.	0.4	21
79	Impaired extracellular matrix degradation in aortic vessels of cirrhotic rats. Journal of Hepatology, 2007, 46, 440-446.	1.8	16
80	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. Gastroenterology, 2007, 133, 2019-2028.	0.6	41
81	Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology, 2007, 46, 1919-1926.	3.6	236
82	Increased Expression of the Renin–Angiotensin System and Mast Cell Density But Not of Angiotensin-converting Enzyme II in Late Stages of Human Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 1117-1125.	0.3	43
83	Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. Hepatology, 2006, 44, 1555-1563.	3.6	49
84	The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver International, 2005, 25, 429-437.	1.9	35
85	Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney International, 2005, 67, 622-630.	2.6	29
86	Sustained aquaretic effect of the V2 -AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. British Journal of Pharmacology, 2005, 146, 654-661.	2.7	15
87	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology, 2005, 41, 579-587.	3.6	79
88	MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. Hepatology, 2005, 41, 1282-1289.	3.6	338
89	Endocannabinoids and liver disease. Hepatology, 2005, 41, 983-985.	3.6	22
90	Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology, 2005, 42, 439-447.	3.6	537

#	Article	IF	CITATIONS
91	A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology, 2005, 42, 627-634.	3.6	229
92	The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARÎ <sup>3</sup> . Influence of albumin. Journal of Hepatology, 2005, 42, 75-81.	1.8	34
93	A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. Journal of Hepatology, 2005, 43, 92-97.	1.8	14
94	Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. Journal of Hepatology, 2005, 43, 85-91.	1.8	13
95	Microarray Analysis of Endothelial Differentially Expressed Genes in Liver of Cirrhotic Rats. Gastroenterology, 2005, 129, 1686-1695.	0.6	40
96	Neovascularization, Angiogenesis, and Vascular Remodeling in Portal Hypertension. , 2005, , 99-112.		13
97	Plasma endothelin-1 and clinical manifestations of neonatal sepsis. Journal of Perinatal Medicine, 2004, 32, 522-6.	0.6	25
98	Adrenomedullin and vascular endothelial growth factor production by follicular fluid macrophages and granulosa cells. Human Reproduction, 2004, 19, 808-814.	0.4	18
99	5-Lipoxygenase (5-LO) is Involved in Kupffer Cell Survival. Possible Role of 5-LO Products in the Pathogenesis of Liver Fibrosis. Comparative Hepatology, 2004, 3, S19.	0.9	4
100	Effects of contrast media on renal function in patients with cirrhosis: A prospective study. Hepatology, 2004, 40, 646-651.	3.6	61
101	High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. Journal of Hepatology, 2004, 40, 424-430.	1.8	44
102	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. Journal of Hepatology, 2004, 41, 384-390.	1.8	141
103	Endogenous cannabinoids and circulatory dysfunction in cirrhosis. , 2004, , 97-101.		0
104	Clinical need for antidiuretic hormone antagonists in cirrhosis. Hepatology, 2003, 37, 13-15.	3.6	8
105	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology, 2003, 38, 452-459.	3.6	73
106	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology, 2003, 38, 258-266.	3.6	744
107	Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2003, 38, 1210-1218.	3.6	430
108	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology, 2003, 125, 117-125.	0.6	317

#	Article	IF	CITATIONS
109	Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology, 2003, 125, 522-531.	0.6	121
110	Nitric Oxide Synthase 3-Dependent Vascular Remodeling and Circulatory Dysfunction in Cirrhosis. American Journal of Pathology, 2003, 162, 1985-1993.	1.9	69
111	Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. Journal of Hepatology, 2003, 38, 755-761.	1.8	38
112	Inhibition of 5â€lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB Journal, 2003, 17, 1745-1747.	0.2	67
113	Renal Effects of Selective Cyclooxygenase Inhibition in Experimental Liver Disease. Advances in Experimental Medicine and Biology, 2003, 525, 133-136.	0.8	0
114	Increased plasma levels of neuropeptide Y in hepatorenal syndrome. Journal of Hepatology, 2002, 36, 349-355.	1.8	23
115	Chronology of hemodynamic changes in asymptomatic in vitro fertilization patients and relationship with ovarian steroids and cytokines. Fertility and Sterility, 2002, 77, 1178-1183.	0.5	14
116	Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization. Fertility and Sterility, 2002, 78, 1261-1267.	0.5	31
117	Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology, 2002, 122, 85-93.	0.6	222
118	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	3.6	8
119	Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. British Journal of Pharmacology, 2002, 135, 891-900.	2.7	43
120	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology, 2002, 36, 941-948.	3.6	497
121	Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology, 2002, 36, 1172-1179.	3.6	35
122	A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology, 2001, 34, 46-52.	1.8	225
123	Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. Journal of Hepatology, 2001, 34, 222-229.	1.8	24
124	Increased production of vascular endothelial growth factor in peritoneal macrophages of cirrhotic patients with spontaneous bacterial peritonitis. Hepatology, 2001, 34, 487-493.	3.6	37
125	Circulating levels of nitric oxide in successful and unsuccessful implantation after in vitro fertilization and embryo transfer. Relationship to estradiol and progesterone. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 564-569.	1.3	7
126	Increased activity of guanosine 3′-5′-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology, 2000, 31, 304-310.	3.6	18

#	Article	IF	CITATIONS
127	Dysregulation of renal aquaporins and Na-Cl cotransporter in CCl4-induced cirrhosis. Kidney International, 2000, 58, 216-228.	2.6	75
128	Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension. Kidney International, 2000, 57, 664-670.	2.6	40
129	Circulating levels of nitric oxide in successful and unsuccessful implantation after in vitro fertilization and embryo transfer. Relationship to estradiol and progesterone. Acta Obstetricia Et Gynecologica Scandinavica, 2000, 79, 564-569.	1.3	4
130	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology, 2000, 119, 794-805.	0.6	69
131	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology, 2000, 33, 43-48.	1.8	381
132	Ascites and Liver Test Abnormalities During Severe Ovarian Hyperstimulation Syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.2	39
133	Adrenomedullin and nitric oxide in menstrual and in vitro fertilization cycles. Relationship to estradiol. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 626-631.	1.3	6
134	Regulation of cyclooxygenase-2 expression in human mesangial cells - transcriptional inhibition by IL-13. FEBS Journal, 1999, 260, 268-274.	0.2	18
135	Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: Regulation by cytokines and bacterial lipopolysaccharide. Hepatology, 1999, 29, 1057-1063.	3.6	68
136	Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients. Hepatology, 1999, 30, 670-676.	3.6	41
137	Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology, 1999, 116, 1167-1175.	0.6	61
138	Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects. Gastroenterology, 1999, 116, 161-167.	0.6	83
139	Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. American Journal of Gastroenterology, 1999, 94, 994-999.	0.2	11
140	Adrenomedullin and nitric oxide in menstrual and in vitro fertilization cycles. Relationship to estradiol. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 626-631.	1.3	13
141	Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology, 1998, 27, 35-41.	3.6	296
142	Increased renal expression of nitric oxide synthase type III in cirrhotic rats with ascites. Hepatology, 1998, 27, 1191-1199.	3.6	18
143	Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality. Hepatology, 1998, 27, 1227-1232.	3.6	387
144	Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology, 1998, 28, 39-44.	3.6	138

#	Article	IF	CITATIONS
145	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology, 1998, 28, 416-422.	3.6	374
146	Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology, 1998, 28, 851-864.	3.6	237
147	Insulin therapy in type 2 diabetic patients: effects on arterial blood pressure and endothelin-1 plasma levels. Diabetes Research and Clinical Practice, 1998, 41, 151-155.	1.1	1
148	Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology, 1998, 114, 336-343.	0.6	103
149	Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. Journal of Hepatology, 1998, 29, 789-795.	1.8	38
150	Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. Journal of Hepatology, 1998, 28, 639-645.	1.8	64
151	Circulatory Dysfunction in Asymptomaticin VitroFertilization Patients. Relationship with Hyperestrogenemia and Activity of Endogenous Vasodilators1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1489-1493.	1.8	35
152	Gene Expression of Endothelin-1 and ET <sub>A</sub> and ET <sub>B</sub> Receptors in Human Cirrhosis: Relationship with Hepatic Hemodynamics. Journal of Vascular Research, 1998, 35, 186-193.	0.6	92
153	Tetrahydrobiopterin Modulates Cyclooxygenase-2 Expression in Human Mesangial Cells. Biochemical and Biophysical Research Communications, 1997, 241, 7-12.	1.0	9
154	Effect of bacterial lipopolysaccharide on endothelin-1 production in human vascular endothelial cells. Journal of Hepatology, 1997, 26, 81-87.	1.8	35
155	Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. Journal of Hepatology, 1997, 27, 645-653.	1.8	59
156	Urinary endothelin-like immunoreactivity in patients with cirrhosis. Journal of Hepatology, 1997, 27, 810-816.	1.8	15
157	Platelet cytosolic calcium concentration in patients with liver cirrhosis. Journal of Hepatology, 1997, 27, 824-829.	1.8	4
158	Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo. Journal of Hepatology, 1997, 26, 614-620.	1.8	84
159	Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. Journal of Hepatology, 1996, 24, 506-512.	1.8	35
160	Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. Journal of Hepatology, 1996, 25, 916-923.	1.8	57
161	Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 662-667.	1.3	24
162	Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology, 1995, 21, 554-560.	3.6	88

#	Article	IF	CITATIONS
163	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology, 1995, 22, 479-487.	3.6	41
164	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology, 1995, 22, 753-758.	3.6	90
165	Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology, 1995, 22, 915-920.	3.6	65
166	Acetylcholine-induced vasorelaxation in portal hypertensive rats. Hepatology, 1995, 22, 1009-1011.	3.6	2
167	Immunoreactive endothelin plasma levels in severe ovarian hyperstimulation syndrome. Fertility and Sterility, 1995, 64, 65-68.	0.5	17
168	Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology, 1995, 108, 1842-1848.	0.6	59
169	Aquaretic effect of the κ-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology, 1995, 109, 217-223.	0.6	44
170	Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. Journal of Hepatology, 1995, 22, 389-398.	1.8	49
171	Antidiuretic Hormone and the Pathogenesis of Water Retention in Cirrhosis with Ascites. Seminars in Liver Disease, 1994, 14, 44-58.	1.8	85
172	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology, 1994, 20, 30-33.	3.6	55
173	Impaired responsiveness to angiotensin II in experimental cirrhosis. Hepatology, 1994, 20, 266-268.	3.6	14
174	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. Hepatology, 1994, 20, 839-844.	3.6	124
175	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology, 1994, 20, 948-954.	3.6	60
176	Increased nitric oxide—dependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology, 1994, 20, 1615-1621.	3.6	86
177	Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. Journal of Hepatology, 1994, 20, 282-288.	1.8	80
178	Blunted natriuretic response to human urine extracts with Na+, K+-ATPase inhibiting activity in experimental cirrhosis. Journal of Hepatology, 1994, 20, 660-665.	1.8	1
179	Intracellular calcium concentration in vascular smooth muscle cells of rats with cirrhosis. Journal of Hepatology, 1994, 21, 521-526.	1.8	19
180	Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis. Gastroenterology, 1994, 107, 1201-1203.	0.6	21

#	Article	IF	CITATIONS
181	Effect of Dipyridamole on Kidney Function in Cirrhosis. Hepatology, 1993, 17, 59-64.	3.6	33
182	Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology, 1993, 17, 355-360.	3.6	183
183	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. Hepatology, 1993, 17, 788-793.	3.6	136
184	Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. Hepatology, 1993, 18, 367-372.	3.6	142
185	Pathogenesis of sodium retention in cirrhosis. Journal of Hepatology, 1993, 18, 147-150.	1.8	11
186	Circulating levels of endothelin in cirrhosis. Gastroenterology, 1993, 104, 1485-1491.	0.6	198
187	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology, 1993, 105, 229-236.	0.6	820
188	Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Gastroenterology, 1992, 102, 280-286.	0.6	44
189	Effects of somatostatin on renal function in cirrhosis. Gastroenterology, 1992, 103, 1868-1874.	0.6	54
190	Rapid Increase in Plasma Levels of Atrial Natriuretic Peptide After Common Bile Duct Ligation in the Rabbit. Annals of Surgery, 1992, 216, 554-559.	2.1	22
191	Carbon tetrachloride induced cirrhosis in rats: A useful tool for investigating the pathogenesis of ascites in chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 90-97.	1.4	70
192	Assessment of the renin-angiotensin system in cirrhotic patients. Journal of Hepatology, 1992, 15, 179-183.	1.8	59
193	Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. Hepatology, 1992, 15, 343-349.	3.6	201
194	Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertility and Sterility, 1991, 56, 1077-1083.	0.5	73
195	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology, 1991, 100, 494-501.	0.6	78
196	Doses of endothelin have natriuretic effects in conscious rats with cirrhosis and ascites. Kidney International, 1991, 40, 182-187.	2.6	25
197	Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride–induced cirrhosis. Hepatology, 1991, 13, 585-589.	3.6	40
198	Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. Hepatology, 1991, 14, 601-607.	3.6	17

#	Article	IF	CITATIONS
199	Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology, 1990, 98, 146-151.	0.6	208
200	Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology, 1990, 99, 1736-1744.	0.6	179
201	Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrhosis. Hepatology, 1990, 11, 379-386.	3.6	19
202	Natriuretic hormone activity in the urine of cirrhotic patients. Hepatology, 1990, 12, 467-475.	3.6	19
203	Role of altered systemic hemodynamics in the blunted renal response to atrial natriuretic peptide in rats with cirrhosis and ascites. Journal of Hepatology, 1989, 9, 217-226.	1.8	29
204	Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology, 1989, 97, 1294-1299.	0.6	63
205	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. Hepatology, 1988, 8, 636-642.	3.6	170
206	Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology, 1988, 94, 482-487.	0.6	438
207	Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology, 1988, 94, 1493-1502.	0.6	599
208	Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Gastroenterology, 1987, 93, 234-241.	0.6	463
209	Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology, 1985, 5, 245-250.	3.6	117
210	Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method. Hepatology, 1985, 5, 815-818.	3.6	125
211	Effect of Demeclocycline on Renal Function and Urinary Prostaglandin E <sub>2</sub> and Kallikrein in Hyponatremic Cirrhotics. Nephron, 1984, 36, 30-37.	0.9	36
212	Nitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis. , 0, , 105-114.		1